ArticleHemaSphere2026

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.

Stefano Luminari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.